secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2025-02-26T23:59:59+00:00
Accession:  0001193125-25-035882
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Taysha reports FY2024 net loss $89.3M; TSHA-102 well tolerated in all 10 patients across REVEAL trials
--------------------------------------------------------------------------------

- Net loss $89.3M ($0.36/sh) vs $111.6M ($0.96/sh) in FY2023; cash $139.0M, runway into Q4 2026.
- TSHA-102 (Rett syndrome) no treatment-related SAEs or DLTs in all 10 patients (6 high dose, 4 low dose) as of Feb 17, 2025 cutoff.
- Dosing of Part A in both REVEAL Phase 1/2 trials completed; pivotal trial design update expected H1 2025.
- R&D expenses $66.0M (up $9.2M YoY) driven by GMP manufacturing and clinical activities; G&A $29.0M (down $1.0M).
- Safety and efficacy data from high-dose cohorts (n=3 each) and low-dose updates expected H1 2025 for both adolescent/adult and pediatric trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312525035882/0001193125-25-035882-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312525035882/d920809d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-035882

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer